Madrigal Pharmaceuticals, Inc. (MDGL)
499.40
-0.31
(-0.06%)
USD |
NASDAQ |
Oct 02, 16:00
499.58
+0.18
(+0.04%)
Pre-Market: 20:00
Madrigal Pharmaceuticals Gross Profit Margin (Quarterly) : 88.91% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 88.91% |
| March 31, 2026 | 91.25% |
| December 31, 2025 | 92.26% |
| September 30, 2025 | 93.57% |
| June 30, 2025 | 95.56% |
| March 31, 2025 | 96.44% |
| December 31, 2024 | 96.31% |
| September 30, 2024 | 96.06% |
| June 30, 2024 | 93.83% |
| March 31, 2024 | |
| December 31, 2023 | |
| September 30, 2023 | |
| June 30, 2023 | |
| March 31, 2023 | |
| December 31, 2022 | |
| September 30, 2022 | |
| June 30, 2022 | |
| March 31, 2022 | |
| December 31, 2021 | |
| September 30, 2021 | |
| June 30, 2021 | |
| March 31, 2021 | |
| December 31, 2020 | |
| September 30, 2020 | |
| June 30, 2020 |
| Date | Value |
|---|---|
| March 31, 2020 | |
| December 31, 2019 | |
| September 30, 2019 | |
| June 30, 2019 | |
| March 31, 2019 | |
| December 31, 2018 | |
| September 30, 2018 | |
| June 30, 2018 | |
| March 31, 2018 | |
| December 31, 2017 | |
| September 30, 2017 | |
| June 30, 2017 | |
| March 31, 2017 | |
| December 31, 2016 | |
| September 30, 2016 | |
| June 30, 2016 | |
| March 31, 2016 | |
| December 31, 2015 | |
| September 30, 2015 | |
| June 30, 2015 | |
| March 31, 2015 | |
| December 31, 2014 | |
| September 30, 2014 | |
| June 30, 2014 | |
| March 31, 2014 |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Alnylam Pharmaceuticals, Inc. | 76.88% |
| Exelixis, Inc. | 96.71% |
| Insmed, Inc. | 83.71% |
| United Therapeutics Corp. | 87.30% |
| Karyopharm Therapeutics, Inc. | 96.75% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -54.34% |
| Return on Assets | -26.61% |
| Return on Invested Capital | -36.08% |
| Profit Margin (Quarterly) | -15.91% |
| Operating Margin (Quarterly) | -15.46% |
| Return on Net Operating Assets | -134.0% |